About this site

What CJC-1295 Dr. is

CJC-1295 Dr. keeps a casebook on the peer-reviewed research literature covering CJC-1295 — a synthetic GHRH analog developed by ConjuChem Biotechnologies and studied in Phase 1/2 human trials published in 2006. Each entry reads a study closely and cites it. There is no clinic here and no one on staff to treat or prescribe; nothing is compounded, sold, or shipped, and none of it is medical advice.

The 'Dr.' in the domain name marks a stance, not a credential: the position of a careful reader working through the literature, not a clinical practitioner. This casebook holds no consultations, issues no diagnoses or treatment plans, and is tied to no healthcare provider or pharmaceutical seller. Reading it is no substitute for talking with a qualified professional about your own health.

Editorial standards

Every quantitative claim on this site — a dose value, a half-life number, a percentage change, a study outcome — is cited to a peer-reviewed publication. The primary sources are:

• PubMed and PubMed Central (NIH) for indexed peer-reviewed journals
• The original journal publications (accessed via DOI)
• ClinicalTrials.gov for registered trial records where applicable
• WADA prohibited list for anti-doping classification
• FDA regulatory databases for classification and compounding status

Secondary sources, forum posts, and commercial vendor claims are not cited and do not influence the content. Where the published literature is silent, this site says so. Where the evidence base has gaps — as it does for CJC-1295, which has no Phase 3 data and no long-term safety dataset — the gaps are identified explicitly.

This site distinguishes between direct CJC-1295 data (Phase 1 human trials, rodent mechanistic studies) and class-level inferences from related GHRH analog compounds (Schally laboratory's MR-409, MR-502). Extrapolating across GHRH analogs requires caution; this site notes when a finding is class-level rather than compound-specific.

What CJC-1295 Dr. is not

This casebook is not a medical practice, pharmacy, telehealth service, or vendor of any kind. It recommends no doses, no regimens, and no products; it keeps no clinical team; it neither sells nor ships CJC-1295 or any other compound. It is unaffiliated with ConjuChem Biotechnologies, WADA, the FDA, and any laboratory, vendor, or healthcare organization.

The 'Dr.' in the name casts the publication as a careful, informed reader of the literature — not a licensed clinical entity. The distinction is stated plainly so there is no ambiguity: this is a reading held to editorial standards, not a healthcare service held to clinical or pharmacist standards.

CJC-1295 synonyms tracked on this site

CJC-1295 appears in the literature under several names that are not always interchangeable:

• DAC:GRF (Drug Affinity Complex Growth Releasing Factor) — the formal designation from ConjuChem
• Modified GRF 1-29 or Mod GRF 1-29 — technically refers to the variant without the DAC albumin-conjugating group; half-life approximately 30 minutes versus 5.8–8.1 days for CJC-1295 with DAC
• CJC-1295 with DAC — the albumin-conjugated variant with extended half-life
• CJC-1295 without DAC — the non-conjugated variant; pharmacologically distinct
• hGRF(1-29) analog — the generic chemical description

This site covers CJC-1295 with DAC (the form studied in the Teichman et al. 2006 human trials) as its primary subject and notes Modified GRF 1-29 for pharmacokinetic comparison.